Literature DB >> 3070474

A trial of metaproterenol by metered-dose inhaler and two spacers in preschool asthmatics.

P König1, D Gayer, A Kantak, C Kreutz, B Douglass, N L Hordvik.   

Abstract

Because most young children have difficulty in coordination for correct use of metered-dose inhalers (MDI), a trial of two spacer devices attached to MDIs was performed. In 13 children with asthma, aged 2-5 years old, a collapsible bag (Inspir-Ease) and a tube spacer (Aerochamber) were tested in a double-blind crossover trial with metaproterenol (1,300 micrograms). Respiratory resistance was measured by the forced oscillation method. Thirty minutes after metaproterenol administration there was a significant decrease in resistance with both spacers, while no significant change occurred after placebo administration. There was no difference in degree of bronchodilation between the two spacers. It is concluded that metaproterenol can be safely and effectively administered to preschool asthmatics by an MDI with spacer devices.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3070474     DOI: 10.1002/ppul.1950050412

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  4 in total

1.  Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.

Authors:  E Dompeling; A M Oudesluys-Murphy; H M Janssens; W Hop; J G Brinkman; R N Sukhai; J C de Jongste
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

Review 2.  Asthma: a follow up statement from an international paediatric asthma consensus group.

Authors: 
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

3.  Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.

Authors:  Ashwin S Dharmadhikari; Mohan Kabadi; Bob Gerety; Anthony J Hickey; P Bernard Fourie; Edward Nardell
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 4.  Treatment considerations in children aged 0-5 years.

Authors:  P König
Journal:  Lung       Date:  1990       Impact factor: 2.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.